The Leading Community for Trusted Peptide Research & Insights
Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog used for reducing visceral adipose tissue in patients with lipodystrophy. Marketed as Egrifta. Specifically targets deep abdominal fat accumulation.
Summary: Stimulates growth hormone release from the pituitary, promoting targeted lipolysis in visceral fat depots and improving metabolic markers. Mechanisms (reported/proposed across domains): Growth hormone axis • Binds to GHRH receptors on pituitary somatotrophs, triggering growth hormone synthesis and pulsatile release. • Increases insulin-like growth factor 1 (IGF-1) levels, mediating...
FDA Approved
Dose: 1–2 mg · Route: Subcutaneous (SC) · Frequency: 1× daily · Duration: 12–52 weeks